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ABSTRACT
About 90% of all breast cancers can be considered as sporadic, without inherited gene alteration. The 
rest of breast cancers (about 5 to 10%) are considered hereditary, most commonly caused by altera-
tions of BRCA1/2 tumor suppressor genes. Lifetime risks for breast and ovarian cancers are increased 
among BRCA1/2 mutation carriers – 4 to 8 and 10 to 20 fold higher respectively.  Due to the small 
proportion of hereditary form of disease, as well as to the high cost, BRCA testing is not screening test 
for general population. It is addressed to selected part of population that fit to recommended criteria. Full 
coding region sequencing of both genes is “gold standard” for detection of BRCA mutation. Concerning 
BRCA testing in Serbia, complete or partial sequencing of BRCA1/2 coding region was performed in 60 
samples. The presence of 4 BRCA1 known mutations, previously detected elsewhere, has been shown:   
185delAG, C61G, 3447del4 and 5382insC (detected twice). In BRCA1 gene, exon 16, an unclassified 
variant M1652I was found. Polymorphic variants in BRCA1 (8 polymorphisms) and BRCA2 (5 polymor-
phisms) genes were also detected. The majority of found BRCA1 and BRCA2 polymorphic variants are 
the missense ones and their influence on breast/ovarian cancer risk in our population has to be proved. 
Identification of BRCA mutations carriers and establishment of spectra and frequency of BRCA mutations 
should enable introduction of BRCA1/2 testing into the clinical practice of Serbia. 
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I
n Serbia, similarly to Western countries, breast cancer is the most frequent malignancy 
and the leading cause of cancer-related death in females with mortality rate 16.9 (ASRw)
in 2000 year (1). The incidence of breast cancer in Serbia can be described with about 
3700 newly diagnosed cases per year. About 1200 of them are newly diagnosed at the 
Institute for Oncology and Radiology of Serbia. 
About 90% of all breast cancers can be considered as sporadic, without inherited gene 
alteration. The rest of breast cancers (about 5 to 10%) are considered to be hereditary, 
most commonly caused by alterations of tumor suppressor genes BReast CAncer gene 1 
and 2 (BRCA1 and BRCA2). Up to 25%-40% of breast cancer cases under the age 35 years 
KDUERUVGHOHWHULRXV%5&$PXWDWLRQ%5&$DQG%5&$JHQHVKDYHEHHQLPSOLFDWHGLQ
about 50% of all hereditary breast cancers. The frequency of BRCA mutations is 1 in 250 
women. Offspring of BRCA mutation carriers have 50% chance to inherit mutated gene 
allele from one of the parents. 
The most common variant of hereditary breast cancer (HBC) is hereditary breast and ovarian 
cancer (HBOC) syndrome. Besides that, HBC can occur as site-specific one. Contribution 
of BRCA mutations to site specific hereditary breast cancer is the following: about 65% of 
IHPDOHEUHDVWFDQFHUIDPLOLHVDUHDVVRFLDWHGZLWK%5&$%5&$PXWDWLRQVZKHUHDVXSWR
35% site-specific breast cancer is associated with undefined gene mutations. Concerning 
IDPLOLHVZLWK+%2&HYHQXSWRRIFDVHVDUHUHODWHGWR%5&$%5&$PXWDWLRQV
Alterations of some other genes such as p53 (Li-Fraumeni syndrome), PTEN (Cowden 
syndrome), STK11 (Peutz-Jeghers syndrome) can also influence development of hereditary 
breast cancer. Hereditary predisposition related to these genes is very rare (about 1% for 
each of them) and they do not significantly contribute to inherited breast cancer – together 
they account for less than 5% of hereditary breast cancer cases.         
Concerning undefined genes, it is obvious that new breast cancer predisposing gene will 
be discovered. Various candidates for BRCA3 gene are investigated. It has recently been 
shown that CHK2 gene mutations harbor intermediate risk for breast cancer, especially in 
Northern Europe. Alterations of ATM gene that controls development of ataxia telangiecta-
sia – bialleleic mutations in ATM gene results in autosomal disease - are also related to 
hereditary form of breast cancer. Heterozygosity for ATM variants may confer an increased 
risk for breast cancer - it seems that only mutations that are involved in the development 
of ataxia telangiectasia are implicated in hereditary predisposition for breast cancer (3). 
However, due to limited spread in the world and lack of high penetrability, ATM and CHK2 
are not real BRCA3 candidates (4).   
BRCA GENE ALTERATIONS
BRCA1 and BRCA2 genes were identified in the middle of 1990s. BRCA1 gene is comprised 
of 24 exons and located on chromosome 17q21, while BRCA2 gene is even larger than 
BRCA1, with 27 exons mapped on chromosome 13q12. Both genes exhibit similar structure 
with noncoding exon 1 and very large exon 11. Mutation spectra of both genes are also 
very similar, with more than 1300 mutations detected in each gene. BRCA mutations are 
scattered throughout these large genes without clustering. Concerning mutation type, about 
70% of detected mutations are frameshift mutations (consequence is frameshift in open 
reading region), while nonsense (consequence is cessation of protein synthesis), as well as 
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missense mutations (consequence is synthesis of altered protein) contribute with 10% each. 
More than 50% of all mutations are registered only once, meaning that majority of families 
with hereditary predisposition tends to have their own mutation. Somatic BRCA mutations 
have not yet been found in sporadic breast cancers and are very rare in sporadic ovarian 
cancers – mechanism of inactivation of BRCA genes in sporadic cancer is dissimilar to that 
in hereditary ones. Hypermethylation of regulatory region of BRCA1 gene with consequent 
inhibition of transcription and lack of BRCA1 protein expression was reported (5).
BRCA1 and BRCA2 are tumor suppressor genes. They are involved in the processes of DNA 
repair, rather as sensor than as effectors. Cells harboring BRCA mutations exhibit higher 
degree of spontaneous and induced chromosome aberrations, they are more sensitive on 
DNA damaging agents and have higher mutation rate. Both protein products are involved in 
homologous recombinant repair, but for BRCA1 protein product, multiple additional func-
tions are suggested. With the number of other proteins, BRCA1 is involved in nonhomolo-
gous end-joining of double-strand breaks, as well as in nucleotide excision repair. Further, 
BRCA1 protein is involved in X chromosome silencing and chromosome remodeling (6). 
Cells with BRCA mutations show defect in DNA repair by homologous recombination. In 
WKHVDPHWLPH%5&$DQG%5&$PXWDWLRQVOHDGWRKHUHGLWDU\SUHGLVSRVLWLRQIRUEUHDVW
ovarian cancer, which implicates the role of homologous recombinant repair pathway in 
protecting individuals against carcinogenesis (4).
According to classification of genes involved in carcinogenesis on “caretakers” and 
“gatekeepers”, BRCA genes can be considered “caretakers” – genes that are guardians 
of genome, indicating their indirect role in the development of malignant phenotype (7). 
When BRCA genes are inactivated, tumor occurs as the consequence of genome instability 
resulting with high number of mutations in some other “gatekeepers” genes that regulate 
balance between cell proliferation and cell apoptosis. 
After BRCA genes mapping, epidemiological studies aimed to characterize BRCA mutations in 
different ethnic groups started. It was noticed that in some of the ethnicities particular BRCA 
mutations were more frequent than it was expected. For example, among Ashkenazi Jews’ 
KHUHGLWDU\EUHDVWRYDULDQSUHGLVSRVHGIDPLOLHVWZR%5&$GHO$*DQG&DQGRQH
BRCA2 (6174delT) mutations are present with frequency higher than 90% (8, 9). This phe-
nomena is associated with “founder” effect (effect of founder mutation), mostly observed in 
geographically or reproductive isolated populations. Individual from relatively small and isolated 
ethnic group may raise or harbor germ-cell mutation that is rare in this population, but it will 
become more frequent in the next generations due to reproductive isolation. “Founder” mutations 
occur in other populations as well, but they can not be easily registered because of the presence 
of additional BRCA variants that rose in the meantime in reproductively mixed populations. 
Lifetime risk for breast/ovarian cancer in BRCA mutation carriers 
BRCA genes are genes with high, but not absolute penetrability (about 80%). Limited 
penetrability complicates BRCA counseling - not all BRCA mutation carriers will develop 
malignant disease. Identification of BRCA mutation can only be used for the estimation of 
EUHDVWRYDULDQFDQFHUULVN/LIHWLPHULVNIRUEUHDVWFDQFHUDPRQJ%5&$PXWDWLRQFDUUL-
ers ranges between 40-85% (10). Since lifetime risk for breast cancer in general population 
is about 10%, this risk is high. BRCA1 associated breast cancer usually occurs at younger 
age – about 50% of all BRCA1 associated breast cancers are diagnosed under age 41 (11). 
BRCA1 mutations cause bilateral breast cancer (lifetime risk is up to 60%). BRCA1 associ-
ated ovarian cancer develops with lifetime risk up to 40% (10), while ovarian cancer risk in 
general female population is about 2%. With occurrence of BRCA1 mutations, appearance 
of some other malignant tumors such as colon carcinoma, prostate cancer etc is associ-
ated. In BRCA2 mutation carriers, lifetime risk for female breast cancer is similar to those 
characteristic for BRCA1 mutation carriers (40 to 85%). Besides this, elevated lifetime risk 
for male breast cancer is related to BRCA2 mutation (lifetime risk is 6%). Ovarian cancer 
risk in BRCA2 mutation carriers is about 20% (10). Hereditary prostate cancer is mostly 
associated with BRCA2 mutations. It is likely that different BRCA mutations are associated 
with different risk for the development of the disease (12). 
Identification of individuals as potential BRCA1/2 carriers 
,GHQWLILFDWLRQRI%5&$PXWDWLRQFDUULHUVLQIDPLOLHVZLWKSRVLWLYHIDPLO\KLVWRU\RIEUHDVW
ovarian cancer is important, since it is now possible to recommend them options for life 
style, surveillance or risk reduction. However, due to the small proportion of hereditary form 
of disease, as well as to the high cost, BRCA testing is not screening test for general popu-
lation. It is addressed to selected part of population that fit to recommended criteria. Genetic 
testing is multi-step process, which includes identification of individuals at risk, pre-test 
counseling, informed consent giving, laboratory test performing, disclosing of result and 
post-test counseling. First step in genetic testing process is identification of the individuals 
WKDWSUREDEO\FDUU\%5&$PXWDWLRQV)DPLO\FOXVWHULQJRIEUHDVWDQGRURYDULDQFDQFHU
bilateral breast cancer and male breast cancer indicate the presence of BRCA mutations 
(Table 1). Ethnicity can also point out the need for BRCA testing – for example, Ashkenazi 
-HZVKDYHKLJKHULQFLGHQFHRI%5&$PXWDWLRQVWKDQRWKHUHWKQLFDOJURXSV
Table 1.,GHQWLILFDWLRQRILQGLYLGXDOVDWULVNIRU%5&$DVVRFLDWHGEUHDVWFDQFHU
Multiple cases of breast cancer from the same side of family tree (especially 
early onset, under 50 years old)
2YDULDQFDQFHUZLWKIDPLO\KLVWRU\ZLWKEUHDVWRYDULDQFDQFHU
 Breast and ovarian cancer occurrence in the same person
Bilateral breast cancer
Male breast cancer
Ashkenazi Jewish origin
Genetic testing must be performed in specialized medical institution, with highly trained 
multidisciplinary team.            
Since we are looking for germ-line mutation, BRCA testing is performed in the sample 
of peripheral blood.  Full coding region sequencing (determination of DNA purine and 
pyrimidine bases order in gene region) of both genes is “gold standard” for detection 
of BRCA mutation. When in one family BRCA1 or BRCA2 mutation is detected, other 
members of the family can be tested only for this mutation. Results of BRCA testing can 
be positive (presence of mutation), negative (absence of mutation) or uninformative (pres-
ence of unclassified variant). Negative result of BRCA testing for the member of family with 
previously detected family mutation is real negative result. When family mutation is not yet 
detected, negative result of BRCA testing must be considered carefully – maybe risk for 
disease is related to some unidentified mutation (13). In addition, the result of testing can 
be the presence of unclassified variant for which it is not yet clear, due to the lack of data, 
if it is deleterious mutation or benign polymorphic variant. 
The particular problem of BRCA testing is the presence of polymorphic variants. In fact, 
synonymous mutations can be considered as true polymorphisms because they do not 
cause amino acid change in protein product. On the other hand, classification of missense 
variants, which lead to the altered amino acid sequence in the protein product, is not 
simple. Altered protein structure and function has to be analyzed to determine whether 
amino acid change alters the folding of the polypeptide or the function of the protein. If the 
folding is not interrupted, it remains to be established whether changed amino acid resides 
in the part of the protein important for its function and, if so, is the protein function altered 
due to this amino acid change. Literature data suggest that the majority of polymorphic 
YDULDQWVUHJDUGOHVVRIV\QRQ\PRXVRUPLVVHQVHW\SHKDUERUORZRUPRGHUDWHEUHDVW
RYDULDQFDQFHUULVN,WLVOLNHO\WKDWVRPHRI%5&$SRO\PRUSKLVPVFDQDOWHUEUHDVW
RYDULDQFDQFHUULVNWKURXJKRXWPRGLI\LQJSHQHWUDQFHRIGHOHWHULRXV%5&$PXWDWLRQVLQ
BRCA1 mutation carriers. It has been reported that BRCA1 wild-type polymorphic allele 
*O\(FDQLQFUHDVHULVNIRURYDULDQFDQFHULQ%5&$PXWDWLRQFDUULHUV
Otherwise, recent data show HH genotype of the amino acid substitution polymorphism 
N372H in the BRCA2 do not elevate the risk of breast and ovarian cancer in BRCA1 muta-
tion carriers (16). ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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Individuals with confirmed BRCA mutations, particularly demand genetic counseling, since 
they are faced with serious dilemmas concerning surveillance or risk reduction (17), as well 
as with the consequence on their offspring.
Pathobiological characteristics of BRCA1/2 associated breast/ovar-
ian cancer
BRCA1 and BRCA2 associated breast tumors exhibit certain morphological and immuno-
histochemical characteristics. BRCA1 associated breast tumors are often pure differenti-
ated invasive ductal carcinomas. Medullary histology is also more common. Concerning 
histological grade, BRCA1 breast carcinomas are predominantly high grade tumors (up to 
84% of them). In the majority of cases (up to 90%), they are estrogen independent, since 
they do not express estrogen as well as progesterone receptors. Up to 95% of BRCA1 and 
BRCA2 tumors do not express Her-2 receptors. Histology of BRCA2 breast tumors is more 
similar to sporadic breast cancer (18). 
BRCA1 and BRCA2 associated ovarian cancer is exclusively of epithelial origin, with high 
grade and predominantly serous histology.    
BRCA testing in Serbia
Investigations on BRCA genes in Serbia started in the end of nineties in collaboration of 
the Institute for Oncology and Radiology of Serbia with National Institute of Oncology of 
Hungary, Budapest (19). After the pause, it continued throughout joint research programs 
with National Centre for Scientific Research “Demokritos”, Athens, Greece, 2001 – 2003 
and 2004 – 2006 (20). Both of collaborations, especially the one with Greece, which 
included possibility of more than one working visit, strengthened orientation toward BRCA 
testing at the Institute for Oncology and Radiology of Serbia. During 2004, the Institute, with 
financial support of Ministry of Science of Serbia, purchased refurbished ABI PRISM 310 
genetic analyzer that enabled complete BRCA testing in our institution. 
Firstly, it was necessary to make the conditions for blood and tissue samples, as well as 
DNA storage. Since we have already been equipped with liquid nitrogen containers, tis-
sue and cell samples, as well as DNA samples for long maintenance, are stored in liquid 
QLWURJHQRQ&
Besides storage conditions, the most important step towards BRCA testing is the establish-
PHQWRI5HJLVWU\RIKHUHGLWDU\EUHDVWRYDULDQFDQFHU,Q/DERUDWRU\RI0ROHFXODU*HQHWLFV
the Registry is under construction, mainly based on medical records from Institute for 
Oncology and Radiology of Serbia.  
Genomic DNA bank is consisted of about 220 blood samples from the individuals at risk 
IRUKHUHGLWDU\EUHDVWDQGRURYDULDQFDQFHU7KHLQGLYLGXDOVDUHLQFOXGHGLQWKHSURFHVVRI
blood and data collection according to established criteria. From 2004, subjects are signing 
inform consent, approved by Ethics Committee of the Institute. 
$ERXW  RI LQFOXGHG LQGLYLGXDOV DUH EUHDVWRYDULDQ FDQFHU SDWLHQWV 7KH PDMRULW\ RI
families included in our bank are represented by one member only. Generally, relatives 
RIEUHDVWRYDULDQFDQFHUSDWLHQWVUHIXVHWREHWHVWHG²LQSDUWEHFDXVHRILQVXIILFLHQW
awareness of genetic testing and in part because of lack of appropriate procedures for risk 
reduction (only invasive prevention strategies such as prophylactic surgery demonstrates 
relevant results in risk reduction). 
6RIDUFRPSOHWHRUSDUWLDOVHTXHQFLQJRI%5&$FRGLQJUHJLRQZDVSHUIRUPHGLQ
samples. 5 BRCA1 mutations were detected in the examined group (Figure 1). The pres-
ence of 4 known mutations, previously detected elsewhere, has been shown:  185delAG 
(exon 2), C61G (exon 5) 3447del4 (exon 11) and 5382insC (exon 20) which was detected 
twice. All identified mutations except one missense mutation (C61G) were frameshift 
mutations. 
7KUHHPXWDWLRQVZHUHGHWHFWHGLQVLWHVSHFLILFEUHDVWFDQFHURQHLQEUHDVWRYDULDQFDQFHU
family and another one in family with ovarian cancer only.
Concerning the age of onset, mutations were detected at extremely young age (22 years) in 
one proband with ovarian cancer whose mother developed breast cancer at age 30.
Figure 1. Proportion of each of mutation type among detected BRCA1 mutations
Besides deleterious mutations, in BRCA1 gene, exon 16, we detected an unclassified variant 
M1652I. This variant has been detected in young female who developed breast cancer at 
age 20. Six months later she developed Hodgkin disease. The influence of this BRCA1 vari-
ant on breast cancer risk is unclear. Further analysis concerning its position in BRCA1 gene, 
as well as the impact on developing malignant disease has to be conducted.    
We also detected polymorphic variants in BRCA1 (8 polymorphisms, Table 2) and BRCA2 
(5 polymorphisms, Table 3) genes. Among them, in BRCA2 gene are two variants that have 
not yet been registered in BIC base. According to mutation type both are missense with 
consequent amino acid change in BRCA2 protein. Since both of them have been detected in 
SUREDQGVZLWKEUHDVWRURYDULDQFDQFHULWLVSRVVLEOHWKDWWKHLULQIOXHQFHRQEUHDVWRYDULDQ
cancer risk will be of significance. They can be classified as unclassified variants whose 
importance has to be further clarified. 
7KHPDMRULW\RI%5&$DVZHOODV%5&$SRO\PRUSKLFYDULDQWVDUHDFFRUGLQJ
to mutation type, missense ones (Figures 2a and 2b). 
BRCA1 variants


Missense
Synonymous
BRCA2 variants


Missense
Synonymous
Figure 2. a. Proportion of missense and synonymous variants found in BRCA1 gene; b. Proportion of 
missense and synonymous variants found in BRCA2 geneZZZRQNQVDF\X$UFKLYH'HFHPEHU
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Table 2. Detected BRCA1 variants
EXON MUTATION AA CHANGE
MUTATION
TYPE
MUTATION
EFFECT*
11
2430T>C
(L771)
Leu>Leu Synonymous Polymorphism
11
2731C>T
(P871L)
Pro>Leu Missense Polymorphism
11
1186A>G
(Q356R)
Gln>Arg Missense Polymorphism
11
2201C>T
(S694S)
Ser>Ser Synonymous Polymorphism
11
3232A>G
(E1038G)
Glu>Gly Missense Polymorphism
11
3667A>G
(K1183R)
Lys>Arg Missense Polymorphism
13
4427T>C
(S1436S)
Ser>Ser Synonymous Polymorphism
16
4956A>G
(S1613G)
Ser>Gly Missense Polymorphism
16
5075G>A
(M1652I)
Met>Ile Missense
Unclassified
variant
*According to Breast Cancer Information Core (KWWSUHVHDUFKQKJULQLKJRYELF)
Table 3. Detected BRCA2 variants
EXON MUTATION AA CHANGE MUTATION 
TYPE
MUTATION 
EFFECT*
10 1342C>A
(H372N)
His>Asn Missense Polymorphism
10 2024T>C
(S599F)
Ser>Phe Missense Not yet 
registered
11 4035T>C
(V1269V)
Val>Val Synonymous Polymorphism
11 3624A>G
(K1132K)
Lys>Lys Synonymous Polymorphism
11 3941T>C
(V1238A)
Val>Ala Missense Not yet 
registered
*According to Breast Cancer Information Core (KWWSUHVHDUFKQKJULQLKJRYELF)
3DUWLFXODUTXHVWLRQLVLIWKHULVNIRUEUHDVWRYDULDQFDQFHUDVVRFLDWHGZLWKSRO\PRUSKLFYDULDQWV
in the cases with more than one of them in the same individual, can be simply added to each 
RWKHUVWD\LQJLQWKHUDQJHRIORZPRGHUDWHULVNRUWKHLUFRPELQDWLRQFDQVLJQLILFDQWO\DOWHU
the risk to be rather moderate or even high. The obtained results support this dilemma. For 
example, all found BRCA1 polymorphic variants were detected in one proband - young female 
who developed breast cancer at age 20 and six months later she developed Hodgkin disease.
FUTURE DIRECTIONS
%5&$WHVWLQJLVRIYDOXHLQWKHHVWLPDWLRQRIIDPLOLDOULVNIRUEUHDVWDQGRYDULDQFDQFHU
It has been proved that BRCA associated, especially BRCA1 associated carcinomas, have 
special pathological characteristics, which can be relevant for treatment and prognosis. 
&ODULI\LQJWKHUROHRI%5&$JHQHVLQPDLQWHQDQFHRIJHQRPHVWDELOLW\WKURXJKRXW'1$
UHSDLUV\VWHPVLVEHJLQQLQJWRVXJJHVWSRWHQWLDOWKHUDSHXWLFXVHVLQFH%5&$PXWDWHG
tumors may be more sensitive to DNA cross-linking agents.  
Recommended whole gene analysis, on the contrary to countries with identified founder 
mutations, besides expensive and to small audience directed BRCA testing, makes difficult 
population-based screening.  That raises dilemma in the country with limited resources 
- what is better to do: to recognize our recurrent mutations even if they are not as highly 
recurrent as in Israel, Poland etc. and to wide-spread BRCA testing, or to do sequencing of 
the entire coding region of the gene, that is more precise and covers almost all mutations, 
but it is directed to the small audience? For our country, this problem is pointed out, due to 
the lack of population-based studies of hereditary breast and ovarian cancer and missing 
data with follow-up of BRCA mutation carriers (21). 
Identification of BRCA mutations carriers, establishment of spectra and frequency of BRCA 
mutations, especially for those with developed breast cancer, together with long-term 
follow-up of mutations carriers, should allow the research on the factors affecting BRCA 
genes penetrability. Systemic BRCA analysis will enable introduction of genetic testing pro-
cess into the clinical practice of Serbia, resulting with the real benefit for mutation carriers 
that are highly vulnerable part of population.   
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